{"entity":{"id":"nct06012695","kind":"trial","name":"NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma","aka":[],"tldr":"A phase 1/2 trial of Temozolomide in advanced solid tumours, run by Novelwise Pharmaceutical Corporation, now recruiting.","summary":"NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma is a phase 1/2 interventional study registered as NCT06012695 by Novelwise Pharmaceutical Corporation, with 79 participants planned, started 2023-08-11 and due to reach its primary completion in 2028-05-30. Interventions recorded: NBM-BMX Capsule, Temozolomide and Standard radiotherapy.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06012695","url":"https://clinicaltrials.gov/study/NCT06012695"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["temozolomide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06012695","phase":"1/2","setting":"A Phase Ib/II, Open-label Study of NBM-BMX as Monotherapy or in Combination With Radiotherapy and Temozolomide in Subjects With Solid Tumors or Newly Diagnosed Glioblastoma","sponsor":"Novelwise Pharmaceutical Corporation","enrolled":79,"outcomes":[]},"route":"/trials/nct06012695/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}]}}